Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.55 |
| ▸ | ACLY | P53396 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605439 | 0.89 | PTGES2 (0.52) | MEN1KMT2AGAAPTGES2ACLY | |
| SCHEMBL7592771 | 0.86 | MEN1 (0.74) | MEN1KMT2AGAAPTGES2ACLY | |
| SCHEMBL7588697 | 0.84 | PTGES2 (0.74) | MEN1KMT2AGAAPTGES2ACLY | |
| SCHEMBL5595863 | 0.83 | MEN1 (0.49) | MEN1KMT2AGAAPTGES2ACLY | |
| SCHEMBL2533357 | 0.82 | KMT2A (0.64) | MEN1KMT2AGAAACLYLMNA | |
| SCHEMBL7572596 | 0.81 | MEN1 (0.67) | MEN1KMT2AGAAPTGES2ACLY | |
| SCHEMBL10143421 | 0.80 | MEN1 (0.66) | MEN1KMT2AGAAPTGES2ACLY | |
| SCHEMBL15761593 | 0.79 | PPARG (0.58) | MEN1KMT2APPARG | |
| SCHEMBL14601698 | 0.79 | LMNA (0.56) | KMT2AACLYLMNA | |
| SCHEMBL10338448 | 0.79 | PSEN1 (0.60) | MEN1KMT2AMAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| EP-1239852-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | Arrow Therapeutics Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001028537-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | ARROW THERAPEUTICS LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | MEN1 2248/4885KMT2A 4634/4885GAA 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.